BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 16845708)

  • 21. Predictors of damage progression in Portuguese patients with systemic lupus erythematosus.
    Santos MJ; Vinagre F; Nero P; Barcelos F; Barcelos A; Rodrigues AM; de Matos AA; Silva C; Miranda L; Capela S; Marques A; Branco J; da Silva JC
    Ann N Y Acad Sci; 2009 Sep; 1173():822-8. PubMed ID: 19758234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and serologic factors associated with lupus pleuritis.
    Mittoo S; Gelber AC; Hitchon CA; Silverman ED; Pope JE; Fortin PR; Pineau C; Smith CD; Arbillaga H; Gladman DD; Urowitz MB; Zummer M; Clarke AE; Bernatsky S; Hudson M; Tucker LB; Petty RE; ; Peschken CA
    J Rheumatol; 2010 Apr; 37(4):747-53. PubMed ID: 20110526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.
    Nossent J; Cikes N; Kiss E; Marchesoni A; Nassonova V; Mosca M; Olesinska M; Pokorny G; Rozman B; Schneider M; Vlachoyiannopoulos PG; Swaak A
    Lupus; 2007; 16(5):309-17. PubMed ID: 17576731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis.
    Ståhl-Hallengren C; Jönsen A; Nived O; Sturfelt G
    J Rheumatol; 2000 Mar; 27(3):685-91. PubMed ID: 10743809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rate and pattern of organ damage in late onset systemic lupus erythematosus.
    Maddison P; Farewell V; Isenberg D; Aranow C; Bae SC; Barr S; Buyon J; Fortin P; Ginzler E; Gladman D; Hanly J; Manzi S; Nived O; Petri M; Ramsey-Goldman R; Sturfelt G;
    J Rheumatol; 2002 May; 29(5):913-7. PubMed ID: 12022349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.
    Cook RJ; Gladman DD; Pericak D; Urowitz MB
    J Rheumatol; 2000 Aug; 27(8):1892-5. PubMed ID: 10955329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus.
    Gutiérrez-Suárez R; Ruperto N; Gastaldi R; Pistorio A; Felici E; Burgos-Vargas R; Martini A; Ravelli A
    Arthritis Rheum; 2006 Sep; 54(9):2989-96. PubMed ID: 16947634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
    Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
    Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage.
    Ruperto N; Buratti S; Duarte-Salazar C; Pistorio A; Reiff A; Bernstein B; Maldonado-Velázquez MR; Beristain-Manterola R; Maeno N; Takei S; Falcini F; Lepore L; Spencer CH; Pratsidou-Gertsi P; Martini A; Ravelli A
    Arthritis Rheum; 2004 Jun; 51(3):458-64. PubMed ID: 15188334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent major infections in juvenile-onset systemic lupus erythematosus--a close link with long-term disease damage.
    Lee PP; Lee TL; Ho MH; Wong WH; Lau YL
    Rheumatology (Oxford); 2007 Aug; 46(8):1290-6. PubMed ID: 17522097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
    Ibañez D; Gladman DD; Urowitz MB
    J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort.
    Lopez R; Davidson JE; Beeby MD; Egger PJ; Isenberg DA
    Rheumatology (Oxford); 2012 Mar; 51(3):491-8. PubMed ID: 22109798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accrual of organ damage over time in patients with systemic lupus erythematosus.
    Gladman DD; Urowitz MB; Rahman P; Ibañez D; Tam LS
    J Rheumatol; 2003 Sep; 30(9):1955-9. PubMed ID: 12966597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected].
    Chaiamnuay S; Bertoli AM; Fernández M; Apte M; Vilá LM; Reveille JD; Alarcón GS;
    J Clin Rheumatol; 2007 Jun; 13(3):128-33. PubMed ID: 17551377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison.
    Gladman DD; Goldsmith CH; Urowitz MB; Bacon P; Fortin P; Ginzler E; Gordon C; Hanly JG; Isenberg DA; Petri M; Nived O; Snaith M; Sturfelt G
    J Rheumatol; 2000 Feb; 27(2):373-6. PubMed ID: 10685799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study.
    Laustrup H; Voss A; Green A; Junker P
    Lupus; 2010 Mar; 19(3):239-46. PubMed ID: 19946037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cigarette smoking and cutaneous damage in systemic lupus erythematosus.
    Turchin I; Bernatsky S; Clarke AE; St-Pierre Y; Pineau CA
    J Rheumatol; 2009 Dec; 36(12):2691-3. PubMed ID: 19884279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus.
    Tomietto P; Annese V; D'agostini S; Venturini P; La Torre G; De Vita S; Ferraccioli GF
    Arthritis Rheum; 2007 Dec; 57(8):1461-72. PubMed ID: 18050188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.
    Moore AD; Clarke AE; Danoff DS; Joseph L; Bélisle P; Neville C; Fortin PR
    J Rheumatol; 1999 Jun; 26(6):1285-90. PubMed ID: 10381044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.